Viewing Expert Gordon Reid | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Viewing Expert

Gordon Reid , President

GoodReid Investment Counsel

Address
47 Colborne Street
Suite 400
Toronto, ON
M5E 1P8

Contact Info
Telephone: 416.364.0890
Toll Free: 1.888.466.3734
Fax: 416.364.1788
Email:


Date Signal Chart Symbol Company Opinion Price
2017-09-19 N/A Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Market.There are reasons to be optimistic going forward, but you have to be realistic about where equities are going. We haven’t had a correction of 5% or more for a very long time. Corrections happen all the time, and we have to expect that they are going to come from time to time. However, the underpinnings of the market are very strong. Corporate earnings are strong. We are seeing a synchronized economic expansion throughout the world. If you look at the developed world, it is hard to find a country that is not in a growth mode. Markets are very long-term vehicles. If we don’t get a correlated move between the economy and the market, we as investors think something is wrong. We have to look at things over cycles and over a long period of time. Sometimes markets get ahead of the fundamentals and sometimes the fundamentals get ahead of markets.


Price:
$0.020
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
_N/A
2017-09-19 STRONG BUY Must be logged in to use chart AAPL-Q Apple

(Market Call Minute.) It has moved up a little in terms of market multiple, but we have repatriation out there with the iPhone 8 and iPhone 10. It has a 93% loyalty rate and there are a billion installed devices.


Price:
$158.730
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-09-19 COMMENT Must be logged in to use chart ABBV-N AbbVie Inc.

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.


Price:
$86.370
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-09-19 DON'T BUY Must be logged in to use chart AIG-N American International Group

Had owned this until about a year ago, and then moved aside. Had some difficulties with management. Even against their peer group in the insurance space, this company is not operating that efficiently.


Price:
$59.490
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-09-19 HOLD Must be logged in to use chart AMGN-Q Amgen Inc.

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.


Price:
$186.320
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-09-19 COMMENT Must be logged in to use chart AMT-N American Tower

A bit of a complicated valuation exercise when you look at it, because it looks expensive on a price/earnings ratio, but really is not. It’s treated more like a real estate investment trust. The street looks at it on an adjusted funds from operations standpoint. When you look at it that way, it compares reasonably well against its major competitors. Growing very well internationally, but stumbling a little domestically. If you take a position, do it as part of a balanced portfolio. He wouldn’t put a lot of risk capital into it.


Price:
$140.980
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-09-19 COMMENT Must be logged in to use chart BA-N Boeing

Owned this for many years, but just sold it a month ago, because it had done so well. As the price of something rises, its value tends to drop. This is trading at about a 50% premium to its 10-year historical average. That represents a lot of risk. He would love to buy it back, but it is a little overpriced as a stock.


Price:
$252.460
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-09-19 COMMENT Must be logged in to use chart BAC-N Bank of America

He continues to like this. Every 1% increase in interest rates will be beneficial to the company by about $5 billion to the bottom line. If you back that through their P&L shares outstanding, it’s about $0.50 a share. A very, very accretive thing for the company. There is lots of gas left in the banks, and particularly in this one.


Price:
$24.860
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-09-19 PAST TOP PICK Must be logged in to use chart C-N CitiGroup

(A Top Pick Oct 18/16. Up 47%.) With the Fed moving, and the banks repairing their balance sheets, he knew things were going to get better.


Price:
$71.150
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-09-19 TOP PICK Must be logged in to use chart CELG-Q Celgene Corp

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)


Price:
$143.470
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-09-19 DON'T BUY Must be logged in to use chart CSCO-Q Cisco

This probably hit its peak 15 or 20 years ago. It was one of the leaders in computer systems, switches and routers. Since then, it has struggled to find its place. It ran into stiff competition, and then fell behind. There have been resurgences from time to time, but it really hasn’t made any headway for many years. The stock has moved, but more on an emotional/sentiment basis.


Price:
$32.490
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-09-19 DON'T BUY Must be logged in to use chart EFX-N Equifax Inc.

He wouldn’t go anywhere near this company following their problems with the cyber attack. You just don’t know what is going to happen. In these situations, especially in the US, a very litigious environment, there is going to be a significant amount of piling on here.


Price:
$94.870
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-09-19 BUY Must be logged in to use chart FB-Q Facebook

This has a lot of runway in front of it. It has appreciated very quickly from a price standpoint, but valuation metrics have become more compelling. For that to happen, it means the fundamentals have risen at a faster pace than the price. They’ve made a very good inroad into artificial intelligence. Their product, Oculus is going to be very important for them. Instagram is doing extremely well.


Price:
$172.520
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-09-19 DON'T BUY Must be logged in to use chart GE-N General Electric

(Market Call Minute.) Changing CEOs, which is a good thing. He wouldn’t touch this yet. The first thing that happens when a new CEO comes on is that they throw everything out, plus the kitchen sink.


Price:
$24.200
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-09-19 TOP PICK Must be logged in to use chart LEA-N Lear Corp.

Automotive seating systems. Trading at less than 9X earnings. Growing rapidly and well-managed. The auto industry is more than just North America. About 17 ½ million units out of N.A., 22 million out of Europe and about 26 million out of China. Dividend yield of 1.2%. (Analysts’ price target is $167.)


Price:
$166.300
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 2,038 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.